Core Insights - C4 Therapeutics, Inc. is expected to report a quarterly loss of $0.37 per share, reflecting a year-over-year change of +49.3%, with revenues projected at $6.88 million, an increase of 158.7% from the previous year [1] Group 1: Stock Performance - C4 Therapeutics shares increased by 13.7% in the last trading session, closing at $7.38, with notable trading volume compared to typical sessions, and a total gain of 56.8% over the past four weeks [2] - The rise in stock price is linked to positive investor sentiment regarding the progress of C4's clinical pipeline, particularly the evaluation of cemsidomide (CFT7455) for multiple myeloma and non-Hodgkin lymphomas [3] Group 2: Earnings and Estimates - The consensus EPS estimate for C4 Therapeutics has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [5] - C4 Therapeutics holds a Zacks Rank of 3 (Hold), similar to Praxis Precision Medicines, which also has a consensus EPS estimate unchanged at -$2.39, representing a year-over-year change of +67.5% [5][6]

WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking ...

Company Overview - C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop new medicines that can transform patients' lives [2][4] - The company is leveraging its TORPEDO® platform to design and optimize small-molecule medicines aimed at difficult-to-treat diseases, particularly in oncology [4] Clinical Trial Information - C4T announced preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors [2][3] - The presentation of these preliminary results will take place at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, on September 14, 2024 [2][3] - CFT1946 is designed to be potent and selective against BRAF V600X mutant targets and has shown activity in preclinical studies in models with BRAF V600E driven disease and those resistant to BRAF inhibitors [3] Drug Development Focus - CFT1946 is currently being studied in a Phase 1 dose escalation trial for BRAF V600X mutant solid tumors, including colorectal cancer, melanoma, and non-small cell lung cancer [3] - The company's degrader medicines aim to utilize the body's natural protein recycling system to degrade disease-causing proteins, potentially overcoming drug resistance and improving patient outcomes [4]

Core Viewpoint - C4 Therapeutics has seen a significant increase in earnings estimates, leading to a positive outlook for its stock price in the near term [1][10]. Earnings Estimates and Revisions - Over the past three months, the Zacks Consensus Estimate for C4 Therapeutics has increased by 16.2% [1]. - For the fiscal year ending December 2024, the company is expected to report earnings of -$1.56 per share, reflecting a change of 41.6% from the previous year's reported number [5]. Zacks Rating System - C4 Therapeutics has been upgraded to a Zacks Rank 2, placing it in the top 20% of Zacks-covered stocks based on estimate revisions, indicating potential for stock price appreciation [3][7]. - The Zacks rating system maintains a balanced approach with an equal proportion of 'buy' and 'sell' ratings, with only the top 20% of stocks receiving favorable ratings [2][4]. Impact of Earnings Estimate Revisions - The upward trend in earnings estimates is a strong indicator of the company's improving business fundamentals, which is expected to positively influence stock price [10][13]. - Empirical research shows a strong correlation between earnings estimate revisions and near-term stock movements, making it a critical factor for investment decisions [11][14].

Fireside Chat Details: Event: UBS TPD Day Date/Time: Monday, July 15, 2024 from 12:00 pm ET – 12:30 pm ET C4 Therapeutics (C4T) (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to a ...

Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fu ...

Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth Ron Cooper most recently served as president and chief executive officer of Albireo Pharma, a fully integrated, global, commercial biopharmaceutical company that was acquired by Ipsen in March 2023. Earlier in his career, Mr. Cooper spent nearly 30 years at Bristol-Myers ...

Table of Contents NOTE REGARDING COMPANY REFERENCES i Item 1. Financial Statements. C4 Therapeutics, Inc. Table of Contents See accompanying notes to unaudited condensed consolidated financial statements. Table of Contents Table of Contents See accompanying notes to unaudited condensed consolidated financial statements. Notes to Condensed Consolidated Financial Statements Liquidity and capital resources Note 2. Summary of significant accounting policies Table of Contents The preparation of condensed consoli ...

Financial Performance - Revenue for the quarter increased by 15% compared to the same period last year [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8% due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered two new international markets, contributing to a 20% increase in global sales [4]. - A new distribution partnership was established in Europe, expected to boost market share by 5% in the next fiscal year [1]. - Expansion into the Asian market is underway, with plans to open three new offices by the end of the year [2]. Product Development - Launched three new products in the tech segment, which have already captured 10% of the market share [3]. - R&D investment increased by 25% to accelerate the development of next-generation products [4]. - The company plans to introduce a new line of eco-friendly products by Q4 [1]. Operational Efficiency - Implemented new automation technologies, reducing production costs by 12% [2]. - Supply chain optimization led to a 15% reduction in delivery times [3]. - Employee training programs were enhanced, resulting in a 10% increase in productivity [4]. Strategic Partnerships - Formed a strategic alliance with a leading software provider to enhance product offerings [1]. - Collaborated with a major logistics firm to improve distribution efficiency [2]. - Announced a joint venture with a renewable energy company to develop sustainable solutions [3]. Customer Engagement - Customer satisfaction scores improved by 8% due to enhanced service quality [4]. - Launched a new loyalty program, which has already attracted 50,000 new members [1]. - Increased social media engagement by 30% through targeted marketing campaigns [2]. Regulatory Compliance - Successfully passed all regulatory audits with no major findings [3]. - Implemented new compliance training for all employees to ensure adherence to industry standards [4]. - Enhanced data security measures to meet new GDPR requirements [1]. Sustainability Initiatives - Reduced carbon emissions by 10% through the adoption of green technologies [2]. - Achieved a 20% reduction in water usage across all manufacturing facilities [3]. - Committed to achieving net-zero emissions by 2030 [4]. Workforce Development - Increased employee retention rates by 5% through improved workplace benefits [1]. - Launched a new leadership development program to prepare future executives [2]. - Expanded diversity and inclusion initiatives, resulting in a more balanced workforce [3]. Technology Innovation - Invested $50 million in AI and machine learning technologies to enhance product capabilities [4]. - Developed a proprietary algorithm that improves data analysis efficiency by 30% [1]. - Partnered with a leading tech university to co-develop cutting-edge solutions [2].

Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 08, 2024 (GLO ...